#BEGIN_DRUGCARD DB02377

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
73-40-5

# ChEBI_ID:
16235

# Chemical_Formula:
C5H4N5O

# Chemical_IUPAC_Name:
2-aminopurin-6-one

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.91

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
2080 mg/L (at 37 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Guanine

# HET_ID:
GUN

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C5H4N5O/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H3,6,8,9,10,11)

# InChI_Key:
InChIKey=IOJBSLDWMHFRAL-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00242

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2377

# Mechanism_Of_Action:
Not Available

# Melting_Point:
360 dec °C

# Molecular_Weight_Avg:
150.1182

# Molecular_Weight_Mono:
150.041584775

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1IT7

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.97

# Predicted_LogS:
-1.8

# Predicted_Water_Solubility:
2.53e+00 g/l

# Primary_Accession_No:
DB02377

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
764

# PubChem_Substance_ID:
46507057

# RxList_Link:
http://www.rxlist.com/cgi/generic/thioguanine.htm

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01672

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=Nc2ncnc2C(=O)N1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:05 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Guanine

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
Not Available

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AE000512

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
TM_1596

# Drug_Target_1_Gene_Sequence:
>798 bp
TTAGAACACCTCCACTGCAGTGGTGAGAGCTTTTTCTATTTTACCCTGTGCCATTTTCGT
TGTTCTCACCACTTCTTCGTGTGACAGTCTTCCGTGGGTGATACCGGCTGCCATGTTCGT
CACACAGGAGAATACAACCACTTTGAGTCCACAATGTTTTGCAGCGATCACTTCTGGAAC
GGTTGACATCCCAACAAGATCAGCTCCGAGCTTTTCAAAGACGCGTATCTCAGCTGGCGT
CTCGTAACTTGGTCCAAGGACACCGATGTAAACCCCTTCCTTCAGGCTGAGTCTTTCCTG
GATTTTCCTCGCCCATTCAGGATCAACAACCGAGGACATATCGGGAAACCTCGGACCTAT
CTTTTCGTCGTTTGGACCTCTGAGAGGATTTCTGAACATGAAGTTTATTATGTCTCTCAC
CAGAATGATTTCTCCAGGTTTGAACTCCGGGTTTATCGCACCGGCGGCGTTGGTTACAAC
GACACCTTTCACTCCCACGTATTTTGCCAGATACACGGGAAAAGCCACCGTTGCTGGATC
GTGACCCTCATAAAGGTGAAACCTTCCTGCCATGATCATAACTGGCTTATCGCTTATTCT
TCCAAAAACGAGTTTCCCGCTGTGACCTTCCACGGTAGGTTGTGGGAAGTGAGGAATATC
TTTATAATCTATAATAACAGGGTCTTCCACTTTTTCTATGAAAGGCCCAAAACCGGATCC
CAGGATGATCAAAATGTCCGGTGAAAGGTTCGTTCTTTCACTTATAAACGTCCTTGCTTC
TTCGATCTTTTTCATCAT

# Drug_Target_1_General_Function:
Involved in transferase activity, transferring pentosyl groups

# Drug_Target_1_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4659

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
29173

# Drug_Target_1_Name:
Purine nucleoside phosphorylase

# Drug_Target_1_Number_of_Residues:
265

# Drug_Target_1_PDB_ID:
1VMK

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00896	Mtap_PNP

# Drug_Target_1_Protein_Sequence:
>Purine nucleoside phosphorylase
MMKKIEEARTFISERTNLSPDILIILGSGFGPFIEKVEDPVIIDYKDIPHFPQPTVEGHS
GKLVFGRISDKPVMIMAGRFHLYEGHDPATVAFPVYLAKYVGVKGVVVTNAAGAINPEFK
PGEIILVRDIINFMFRNPLRGPNDEKIGPRFPDMSSVVDPEWARKIQERLSLKEGVYIGV
LGPSYETPAEIRVFEKLGADLVGMSTVPEVIAAKHCGLKVVVFSCVTNMAAGITHGRLSH
EEVVRTTKMAQGKIEKALTTAVEVF

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q9X1T2

# Drug_Target_1_SwissProt_Name:
Q9X1T2_THEMA

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
7.22

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
NP

# Drug_Target_2_GenBank_ID_Gene:
X00737

# Drug_Target_2_GenBank_ID_Protein:
35565

# Drug_Target_2_GeneCard_ID:
NP

# Drug_Target_2_Gene_Name:
PNP

# Drug_Target_2_Gene_Sequence:
>870 bp
ATGGAGAACGGATACACCTATGAAGATTATAAGAACACTGCAGAATGGCTTCTGTCTCAT
ACTAAGCACCGACCTCAAGTTGCAATAATCTGTGGTTCTGGATTAGGAGGTCTGACTGAT
AAATTAACTCAGGCCCAGATCTTTGACTACAGTGAAATCCCCAACTTTCCTCGAAGTACA
GTGCCAGGTCATGCTGGCCGACTGGTGTTTGGGTTCCTGAATGGCAGGGCCTGTGTGATG
ATGCAGGGCAGGTTCCACATGTATGAAGGGTACCCACTCTGGAAGGTGACATTCCCAGTG
AGGGTTTTCCACCTTCTGGGTGTGGACACCCTGGTAGTCACCAATGCAGCAGGAGGGCTG
AACCCCAAGTTTGAGGTTGGAGATATCATGCTGATCCGTGACCATATCAACCTACCTGGT
TTCAGTGGTCAGAACCCTCTCAGAGGGCCCAATGATGAAAGGTTTGGAGATCGTTTCCCT
GCCATGTCTGATGCCTACGACCGGACTATGAGGCAGAGGGCTCTCAGTACCTGGAAACAA
ATGGGGGAGCAACGTGAGCTACAGGAAGGCACCTATGTGATGGTGGCAGGCCCCAGCTTT
GAGACTGTGGCAGAATGTCGTGTGCTGCAGAAGCTGGGAGCAGACGCTGTTGGCATGAGT
ACAGTACCAGAAGTTATCGTTGCACGGCACTGTGGACTTCGAGTCTTTGGCTTCTCACTC
ATCACTAACAAGGTCATCATGGATTATGAAAGCCTGGAGAAGGCCAACCATGAAGAAGTC
TTAGCAGCTGGCAAACAAGCTGCACAGAAATTGGAACAGTTTGTCTCCATTCTTATGGCC
AGCATTCCACTCCCTGACAAAGCCAGTTGA

# Drug_Target_2_General_Function:
Nucleotide transport and metabolism

# Drug_Target_2_General_References:
12928150	Yu L, Kalla K, Guthrie E, Vidrine A, Klimecki WT: Genetic variation in genes associated with arsenic metabolism: glutathione S-transferase omega 1-1 and purine nucleoside phosphorylase polymorphisms in European and indigenous Americans. Environ Health Perspect. 2003 Aug;111(11):1421-7.
1384322	Aust MR, Andrews LG, Barrett MJ, Norby-Slycord CJ, Markert ML: Molecular analysis of mutations in a patient with purine nucleoside phosphorylase deficiency. Am J Hum Genet. 1992 Oct;51(4):763-72.
2104852	Ealick SE, Rule SA, Carter DC, Greenhough TJ, Babu YS, Cook WJ, Habash J, Helliwell JR, Stoeckler JD, Parks RE Jr, et al.: Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 A resolution. J Biol Chem. 1990 Jan 25;265(3):1812-20.
3029074	Williams SR, Gekeler V, McIvor RS, Martin DW Jr: A human purine nucleoside phosphorylase deficiency caused by a single base change. J Biol Chem. 1987 Feb 15;262(5):2332-8.
6087295	Williams SR, Goddard JM, Martin DW Jr: Human purine nucleoside phosphorylase cDNA sequence and genomic clone characterization. Nucleic Acids Res. 1984 Jul 25;12(14):5779-87.
8931706	Pannicke U, Tuchschmid P, Friedrich W, Bartram CR, Schwarz K: Two novel missense and frameshift mutations in exons 5 and 6 of the purine nucleoside phosphorylase (PNP) gene in a severe combined immunodeficiency (SCID) patient. Hum Genet. 1996 Dec;98(6):706-9.

# Drug_Target_2_HGNC_ID:
HGNC:7892

# Drug_Target_2_HPRD_ID:
01247

# Drug_Target_2_ID:
277

# Drug_Target_2_Locus:
14q13.1

# Drug_Target_2_Molecular_Weight:
32118

# Drug_Target_2_Name:
Purine nucleoside phosphorylase

# Drug_Target_2_Number_of_Residues:
289

# Drug_Target_2_PDB_ID:
1RT9

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00896	Mtap_PNP

# Drug_Target_2_Protein_Sequence:
>Purine nucleoside phosphorylase
MENGYTYEDYKNTAEWLLSHTKHRPQVAIICGSGLGGLTDKLTQAQIFDYGEIPNFPRST
VPGHAGRLVFGFLNGRACVMMQGRFHMYEGYPLWKVTFPVRVFHLLGVDTLVVTNAAGGL
NPKFEVGDIMLIRDHINLPGFSGQNPLRGPNDERFGDRFPAMSDAYDRTMRQRALSTWKQ
MGEQRELQEGTYVMVAGPSFETVAECRVLQKLGADAVGMSTVPEVIVARHCGLRVFGFSL
ITNKVIMDYESLEKANHEEVLAAGKQAAQKLEQFVSILMASIPLPDKAS

# Drug_Target_2_Reaction:
purine nucleoside + phosphate = purine + alpha-D-ribose 1-phosphate

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P00491

# Drug_Target_2_SwissProt_Name:
PNPH_HUMAN

# Drug_Target_2_Synonyms:
EC 2.4.2.1
Inosine phosphorylase
PNP

# Drug_Target_2_Theoretical_pI:
6.95

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
X73828

# Drug_Target_3_GenBank_ID_Protein:
929584

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
xapA

# Drug_Target_3_Gene_Sequence:
>873 bp
TCATTTGGCCTCACCCGCGAGGCCGTTTCTTATTGTTTTTCTCAGGCAATTTTGCGCAGA
AAGCCACAAATAAGGTTGATGAGGTTCTGCTTGTGAGCTCGCAGCCGCCAGCGTTTGCGC
ATGTGACAATTTCACATCGCTTAAACCTTCCGCCATATTGGTAATCGCAGAGACCGCAAC
GACTTTAAGGTCGCAATGGCGAGCTGAAATAACCTCAGGCACCACAGACATACCAACAAC
ATCCCCACCAATAATTTGCATCATGCGAATTTCCGCCGCAGTCTCGAAATTCGGCCCCGG
ATACGAGACGAACACGCCCTCCGTCAGAGGGAAACCCTCTTCTTTCGGCCACTTTTTGTA
ACAGTGCGCGGTATTCCGCATCGTAGGCATTTGCCAGTGAGAAGAAGCGCTCTCCAAAAC
GATCATCGTTAAGACCCACCATCGCGTACCGGGCATGGTGTTGATATGATCTTTCAATGC
GACCAGGCTGCCTGCCCCCACTTCCGGACGCAGCGAGCCTGCCGCATTGGTGCAGAACAG
TAGCTCGCAGCCCAGCAGCTTAAAGGTACGAATTGCGTCAGTCATAATGGTCATTCCACG
ACCTTCGTAGAAATGTCCGCGACCTTTCATACATACCACCGGTACGCCCTGGAGATGGCC
CAGCACTAACTCCCCCGCATGACCATGTACCGTACTTACCGGGAAGCCCGGCAGCTTTTC
GTAGGAAATTGCGACAGCGTTCTCAATCTGATCGGCCAGCGCGCCGAGCCCGGAACCTAA
AATAAAGGCCACTCGTGGCGTGAAATCAGGTTTATAAGTCTTGATAATATCTATGCAAAA
CAGCGGGTTATGAGAAAATTGAACCTGAGACAT

# Drug_Target_3_General_Function:
Nucleotide transport and metabolism

# Drug_Target_3_General_References:
7559336	Seeger C, Poulsen C, Dandanell G: Identification and characterization of genes (xapA, xapB, and xapR) involved in xanthosine catabolism in Escherichia coli. J Bacteriol. 1995 Oct;177(19):5506-16.
9205837	Yamamoto Y, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kimura S, Kitagawa M, Makino K, Miki T, Mitsuhashi N, Mizobuchi K, Mori H, Nakade S, Nakamura Y, Nashimoto H, Oshima T, Oyama S, Saito N, Sampei G, Satoh Y, Sivasundaram S, Tagami H, Horiuchi T, et al.: Construction of a contiguous 874-kb sequence of the Escherichia coli -K12 genome corresponding to 50.0-68.8 min on the linkage map and analysis of its sequence features. DNA Res. 1997 Apr 28;4(2):91-113.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2837

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
29835

# Drug_Target_3_Name:
Xanthosine phosphorylase

# Drug_Target_3_Number_of_Residues:
277

# Drug_Target_3_PDB_ID:
1YR3

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00896	Mtap_PNP

# Drug_Target_3_Protein_Sequence:
>Xanthosine phosphorylase
MSQVQFSHNPLFCIDIIKTYKPDFTPRVAFILGSGLGALADQIENAVAISYEKLPGFPVS
TVHGHAGELVLGHLQGVPVVCMKGRGHFYEGRGMTIMTDAIRTFKLLGCELLFCTNAAGS
LRPEVGAGSLVALKDHINTMPGTPMVGLNDDRFGERFFSLANAYDAEYRALLQKVAKEEG
FPLTEGVFVSYPGPNFETAAEIRMMQIIGGDVVGMSVVPEVISARHCDLKVVAVSAITNM
AEGLSDVKLSHAQTLAAAELSKQNFINLICGFLRKIA

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
The nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the nucleoside molecule, with the formation of the corresponding free bases and pentose-1-phosphate. This protein can degrade all purine nucleosides except adenosine and deoxyadenosine

# Drug_Target_3_SwissProt_ID:
P45563

# Drug_Target_3_SwissProt_Name:
XAPA_ECOLI

# Drug_Target_3_Synonyms:
EC 2.4.2.-

# Drug_Target_3_Theoretical_pI:
6.50

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasm

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
X00221

# Drug_Target_4_GenBank_ID_Protein:
41607

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
gpt

# Drug_Target_4_Gene_Sequence:
>459 bp
ATGAGCGAAAAATACATCGTCACCTGGGACATGTTGCAGATCCATGCACGTAAACTCGCA
AGCCGACTGATGCCTTCTGAACAATGGAAAGGCATTATTGCCGTAAGCCGTGGCGGTCTG
GTACCGGGTGCGTTACTGGCGCGTGAACTGGGTATTCGTCATGTCGATACCGTTTGTATT
TCCAGCTACGATCACGACAACCAGCGCGAGCTTAAAGTGCTGAAACGCGCAGAAGGCGAT
GGCGAAGGCTTCATCGTTATTGATGACCTGGTGGATACCGGTGGTACTGCGGTTGCGATT
CGTGAAATGTATCCAAAAGCGCACTTTGTCACCATCTTCGCAAAACCGGCTGGTCGTCCG
CTGGTTGATGACTATGTTGTTGATATCCCGCAAGATACCTGGATTGAACAGCCGTGGGAT
ATGGGCGTCGTATTCGTCCCGCCAATCTCCGGTCGCTAA

# Drug_Target_4_General_Function:
Nucleotide transport and metabolism

# Drug_Target_4_General_References:
3540961	Richardson KK, Richardson FC, Crosby RM, Swenberg JA, Skopek TR: DNA base changes and alkylation following in vivo exposure of Escherichia coli to N-methyl-N-nitrosourea or N-ethyl-N-nitrosourea. Proc Natl Acad Sci U S A. 1987 Jan;84(2):344-8.
6100966	Mulligan RC, Berg P: Factors governing the expression of a bacterial gene in mammalian cells. Mol Cell Biol. 1981 May;1(5):449-59.
6324102	Richardson KK, Fostel J, Skopek TR: Nucleotide sequence of the xanthine guanine phosphoribosyl transferase gene of E. coli. Nucleic Acids Res. 1983 Dec 20;11(24):8809-16.
6324103	Pratt D, Subramani S: Nucleotide sequence of the Escherichia coli xanthine-guanine phosphoribosyl transferase gene. Nucleic Acids Res. 1983 Dec 20;11(24):8817-23.
6396164	Jagadeeswaran P, Ashman CR, Roberts S, Langenberg J: Nucleotide sequence and analysis of deletion mutants of the Escherichia coli gpt gene in plasmid pSV2 gpt. Gene. 1984 Nov;31(1-3):309-13.
6397401	Nuesch J, Schumperli D: Structural and functional organization of the gpt gene region of Escherichia coli. Gene. 1984 Dec;32(1-2):243-9.
9100006	Vos S, de Jersey J, Martin JL: Crystal structure of Escherichia coli xanthine phosphoribosyltransferase. Biochemistry. 1997 Apr 8;36(14):4125-34.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9743633	Vos S, Parry RJ, Burns MR, de Jersey J, Martin JL: Structures of free and complexed forms of Escherichia coli xanthine-guanine phosphoribosyltransferase. J Mol Biol. 1998 Oct 2;282(4):875-89.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
3681

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
16971

# Drug_Target_4_Name:
Xanthine phosphoribosyltransferase

# Drug_Target_4_Number_of_Residues:
152

# Drug_Target_4_PDB_ID:
1A96

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00156	Pribosyltran

# Drug_Target_4_Protein_Sequence:
>Xanthine phosphoribosyltransferase
MSEKYIVTWDMLQIHARKLASRLMPSEQWKGIIAVSRGGLVPGALLARELGIRHVDTVCI
SSYDHDNQRELKVLKRAEGDGEGFIVIDDLVDTGGTAVAIREMYPKAHFVTIFAKPAGRP
LVDDYVVDIPQDTWIEQPWDMGVVFVPPISGR

# Drug_Target_4_Reaction:
9-(5-phospho-beta-D-ribosyl)xanthine + diphosphate = 5-phospho-alpha-D-ribose 1-diphosphate + xanthine

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Acts on guanine, xanthine and to a lesser extent hypoxanthine

# Drug_Target_4_SwissProt_ID:
P0A9M5

# Drug_Target_4_SwissProt_Name:
XGPT_ECOLI

# Drug_Target_4_Synonyms:
EC 2.4.2.22
XGPRT
Xanthine-guanine phosphoribosyltransferase

# Drug_Target_4_Theoretical_pI:
5.63

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cytoplasmic

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
GCH1

# Drug_Target_5_GenBank_ID_Gene:
Z29434

# Drug_Target_5_GenBank_ID_Protein:
7242659

# Drug_Target_5_GeneCard_ID:
GCH1

# Drug_Target_5_Gene_Name:
GCH1

# Drug_Target_5_Gene_Sequence:
>753 bp
ATGGAGAAGGGCCCTGTGCGGGCACCGGCGGAGAAGCCGCGGGGCGCCAGGTGCAGCAAT
GGGTTCCCCGAGCGGGATCCGCCGCGGCCCGGGCCCAGCAGGCCGGCGGAGAAGCCCCCG
CGGCCCGAGGCCAAGAGCGCGCAGCCCGCGGACGGCTGGAAGGGCGAGCGGCCCCGCAGC
GAGGAGGATAACGAGCTGAACCTCCCTAACCTGGCAGCCGCCTACTCGTCCATCCTGAGC
TCGCTGGGCGAGAACCCCCAGCGGCAAGGGCTGCTCAAGACGCCCTGGAGGGCGGCCTCG
GCCATGCAGTTCTTCACCAAGGGCTACCAGGAGACCATCTCAGATGTCCTAAACGATGCT
ATATTTGATGAAGATCATGATGAGATGGTGATTGTGAAGGACATAGACATGTTTTCCATG
TGTGAGCATCACTTGGTTCCATTTGTTGGAAAGGTCCATATTGGTTATCTTCCTAACAAG
CAAGTCCTTGGCCTCAGCAAACTTGCGAGGATTGTAGAAATCTATAGTAGAAGACTACAA
GTTCAGGAGCGCCTTACAAAACAAATTGCTGTAGCAATCACGGAAGCCTTGCGGCCTGCT
GGAGTCGGGGTAGTGGTTGAAGCAACACACATGTGTATGGTAATGCGAGGTGTACAGAAA
ATGAACAGCAAAACTGTGACCAGCACAATGTTGGGTGTGTTCCGGGAGGATCCAAAGACT
CGGGAAGAGTTCCTGACTCTCATTAGGAGCTGA

# Drug_Target_5_General_Function:
Coenzyme transport and metabolism

# Drug_Target_5_General_References:
10076897	Hirano M, Komure O, Ueno S: A novel missense mutant inactivates GTP cyclohydrolase I in dopa-responsive dystonia. Neurosci Lett. 1999 Feb 5;260(3):181-4.
10208576	Brique S, Destee A, Lambert JC, Mouroux V, Delacourte A, Amouyel P, Chartier-Harlin MC: A new GTP-cyclohydrolase I mutation in an unusual dopa-responsive dystonia, familial form. Neuroreport. 1999 Feb 25;10(3):487-91.
10582612	Suzuki T, Ohye T, Inagaki H, Nagatsu T, Ichinose H: Characterization of wild-type and mutants of recombinant human GTP cyclohydrolase I: relationship to etiology of dopa-responsive dystonia. J Neurochem. 1999 Dec;73(6):2510-6.
10825351	Tassin J, Durr A, Bonnet AM, Gil R, Vidailhet M, Lucking CB, Goas JY, Durif F, Abada M, Echenne B, Motte J, Lagueny A, Lacomblez L, Jedynak P, Bartholome B, Agid Y, Brice A: Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain. 2000 Jun;123 ( Pt 6):1112-21.
10987649	Hwu WL, Wang PJ, Hsiao KJ, Wang TR, Chiou YW, Lee YM: Dopa-responsive dystonia induced by a recessive GTP cyclohydrolase I mutation. Hum Genet. 1999 Sep;105(3):226-30.
11113234	Steinberger D, Korinthenberg R, Topka H, Berghauser M, Wedde R, Muller U: Dopa-responsive dystonia: mutation analysis of GCH1 and analysis of therapeutic doses of L-dopa. German Dystonia Study Group. Neurology. 2000 Dec 12;55(11):1735-7.
12391354	Leuzzi V, Carducci C, Carducci C, Cardona F, Artiola C, Antonozzi I: Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive myoclonus-dystonia syndrome. Neurology. 2002 Oct 22;59(8):1241-3.
1482676	Gutlich M, Schott K, Werner T, Bacher A, Ziegler I: Species and tissue specificity of mammalian GTP cyclohydrolase I messenger RNA. Biochim Biophys Acta. 1992 Dec 29;1171(2):133-40.
1520321	Togari A, Ichinose H, Matsumoto S, Fujita K, Nagatsu T: Multiple mRNA forms of human GTP cyclohydrolase I. Biochem Biophys Res Commun. 1992 Aug 31;187(1):359-65.
7501255	Ichinose H, Ohye T, Segawa M, Nomura Y, Endo K, Tanaka H, Tsuji S, Fujita K, Nagatsu T: GTP cyclohydrolase I gene in hereditary progressive dystonia with marked diurnal fluctuation. Neurosci Lett. 1995 Aug 18;196(1-2):5-8.
7730309	Ichinose H, Ohye T, Matsuda Y, Hori T, Blau N, Burlina A, Rouse B, Matalon R, Fujita K, Nagatsu T: Characterization of mouse and human GTP cyclohydrolase I genes. Mutations in patients with GTP cyclohydrolase I deficiency. J Biol Chem. 1995 Apr 28;270(17):10062-71.
7874165	Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M, Nomura Y, Endo K, Tanaka H, Tsuji S, et al.: Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet. 1994 Nov;8(3):236-42.
8068008	Gutlich M, Jaeger E, Rucknagel KP, Werner T, Rodl W, Ziegler I, Bacher A: Human GTP cyclohydrolase I: only one out of three cDNA isoforms gives rise to the active enzyme. Biochem J. 1994 Aug 15;302 ( Pt 1):215-21.
8666288	Witter K, Werner T, Blusch JH, Schneider EM, Riess O, Ziegler I, Rodl W, Bacher A, Gutlich M: Cloning, sequencing and functional studies of the gene encoding human GTP cyclohydrolase I. Gene. 1996 Jun 1;171(2):285-90.
8695054	Nomura T, Ohtsuki M, Matsui S, Sumi-Ichinose C, Nomura H, Hagino Y, Iwase K, Ichinose H, Fujita K, Nagatsu T: Isolation of a full-length cDNA clone for human GTP cyclohydrolase I type 1 from pheochromocytoma. J Neural Transm Gen Sect. 1995;101(1-3):237-42.
8852666	Bandmann O, Nygaard TG, Surtees R, Marsden CD, Wood NW, Harding AE: Dopa-responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity. Hum Mol Genet. 1996 Mar;5(3):403-6.
8957022	Hirano M, Tamaru Y, Ito H, Matsumoto S, Imai T, Ueno S: Mutant GTP cyclohydrolase I mRNA levels contribute to dopa-responsive dystonia onset. Ann Neurol. 1996 Nov;40(5):796-8.
9120469	Beyer K, Lao-Villadoniga JI, Vecino-Bilbao B, Cacabelos R, De la Fuente-Fernandez R: A novel point mutation in the GTP cyclohydrolase I gene in a Spanish family with hereditary progressive and dopa responsive dystonia. J Neurol Neurosurg Psychiatry. 1997 Apr;62(4):420-1.
9222755	Thony B, Blau N: Mutations in the GTP cyclohydrolase I and 6-pyruvoyl-tetrahydropterin synthase genes. Hum Mutat. 1997;10(1):11-20.
9328244	Jarman PR, Bandmann O, Marsden CD, Wood NW: GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs. J Neurol Neurosurg Psychiatry. 1997 Sep;63(3):304-8.
9667588	Furukawa Y, Kish SJ, Bebin EM, Jacobson RD, Fryburg JS, Wilson WG, Shimadzu M, Hyland K, Trugman JM: Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. Ann Neurol. 1998 Jul;44(1):10-6.
9778264	Bandmann O, Valente EM, Holmans P, Surtees RA, Walters JH, Wevers RA, Marsden CD, Wood NW: Dopa-responsive dystonia: a clinical and molecular genetic study. Ann Neurol. 1998 Oct;44(4):649-56.

# Drug_Target_5_HGNC_ID:
HGNC:4193

# Drug_Target_5_HPRD_ID:
02573

# Drug_Target_5_ID:
1673

# Drug_Target_5_Locus:
14q22.1-q22.2

# Drug_Target_5_Molecular_Weight:
27903

# Drug_Target_5_Name:
GTP cyclohydrolase I

# Drug_Target_5_Number_of_Residues:
250

# Drug_Target_5_PDB_ID:
1IS8

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF01227	GTP_cyclohydroI

# Drug_Target_5_Protein_Sequence:
>GTP cyclohydrolase I
MEKGPVRAPAEKPRGARCSNGFPERDPPRPGPSRPAEKPPRPEAKSAQPADGWKGERPRS
EEDNELNLPNLAAAYSSILSSLGENPQRQGLLKTPWRAASAMQFFTKGYQETISDVLNDA
IFDEDHDEMVIVKDIDMFSMCEHHLVPFVGKVHIGYLPNKQVLGLSKLARIVEIYSRRLQ
VQERLTKQIAVAITEALRPAGVGVVVEATHMCMVMRGVQKMNSKTVTSTMLGVFREDPKT
REEFLTLIRS

# Drug_Target_5_Reaction:
GTP + H2O = formate + 2-amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)dihydropteridine triphosphate

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Isoform GCH-1 is the functional enzyme, the potential function of the enzymatically inactive isoforms remains unknown

# Drug_Target_5_SwissProt_ID:
P30793

# Drug_Target_5_SwissProt_Name:
GCH1_HUMAN

# Drug_Target_5_Synonyms:
EC 3.5.4.16
GTP-CH-I

# Drug_Target_5_Theoretical_pI:
8.82

# Drug_Target_5_Transmembrane_Regions:
None

#END_DRUGCARD DB02377
